All In Biotech

Free tool

FAERS Monitor: Ogsiveo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217677 or its brand name (Ogsiveo, Nirogacestat Hydrobromide). Reports on generic versions are filed under their own applications.

Reports

923

Serious

302

33% of reports

Hospitalization

139

Death reported

8

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea323
  • nausea203
  • fatigue177
  • rash120
  • product dose omission issue93
  • headache90
  • vomiting82
  • stomatitis61
  • cough50
  • pruritus48
  • alopecia45
  • intentional underdose42
  • product dose omission in error42
  • abdominal discomfort40
  • dehydration38

Reports by year received

View as table
YearReports
20201
20212
202215
202322
2024563
2025156
2026164

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,236 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
intentional underdoseSignal42131.898.05,292
product dose omission in errorSignal4233.825.21,306
stomatitisSignal6122.918.01,261
diarrhoeaSignal32311.410.43,152
product dose omission issueSignal937.25.9498
dehydrationSignal386.54.8172
rashSignal1206.35.3538
nauseaSignal2035.85.2842
abdominal discomfortSignal405.44.0141
alopeciaSignal455.23.9151
fatigueSignal1775.24.5616
coughSignal504.13.1114
vomitingSignal824.03.2184
headacheSignal903.32.7144
pruritusSignal482.82.257

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.